Following Millennium Merger, Takeda's Hopes Dashed To Be Among Number Three In Japan
This article was originally published in PharmAsia News
Executive Summary
Takeda and Millennium's combined oncology unit has 13 molecules in clinical development, six of which are in Phase II or III, including potential first-in-class opportunities
You may also be interested in...
Takeda To Rely On M&A, Emerging Market Expansion To Offset Patent Losses
Japan's largest drug company Takeda hopes to minimize the impact of looming patent expirations in the U.S. by relying on mergers and acquisitions to increase its pipeline and extend its territory coverage, especially in emerging countries
Takeda To Rely On M&A, Emerging Market Expansion To Offset Patent Losses
Japan's largest drug company Takeda hopes to minimize the impact of looming patent expirations in the U.S. by relying on mergers and acquisitions to increase its pipeline and extend its territory coverage, especially in emerging countries
BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
Bristol-Myers Squibb and Japanese partner Otsuka Pharmaceuticals have entered into a two-part deal that extends their 10-year-old collaboration to sell the blockbuster psychiatric drug Abilify (aripiprazole) in the U.S. and also gives Otsuka a presence in oncology in the U.S., Europe and Japan